Comparative efficacy of long-acting muscarinic antagonist monotherapies in COPD: a systematic review and network meta-analysis

References

• Global Initiative for Chronic Obstructive Lung Disease (GOLD) [database on the internet]Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease2015 Available from: http://www.goldcopd.org/uploads/users/files/GOLD_Report_2015_Apr2.pdfAccessed May 11, 2015
   Google Scholar
• KewKMDiasSCatesCJLong-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysisCochrane Database Syst Rev2014263
   Google Scholar
• TashkinDPCelliBSennSA 4-year trial of tiotropium in chronic obstructive pulmonary diseaseN Engl J Med20083591543155418836213
   PubMed Web of Science ®Google Scholar
• ChanCKNMaltaisFSigouinCHaddonJMFordGTA randomized controlled trial to assess the efficacy of tiotropium in Canadian patients with chronic obstructive pulmonary diseaseCan Respir J20071446547218060091
   PubMed Web of Science ®Google Scholar
• DonohueJFvan NoordJABatemanEDA 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterolChest2002122475512114338
   PubMed Web of Science ®Google Scholar
• JonesPWAgustiAChanezPA phase III study evaluating aclidinium bromide, a novel long-acting antimuscarinic, in patients with COPD: ACCLAIM/COPD IAm J Res Crit Care Med2009179A6180
   Web of Science ®Google Scholar
• D’UrzoAFergusonGTvan NoordJAEfficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trialRespir Res20111215622151296
   PubMed Web of Science ®Google Scholar
• KerwinEHebertJGallagherNEfficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 studyEur Respir J2012401106111423060624
   PubMed Web of Science ®Google Scholar
• TrivediRRichardNMehtaRChurchAUmeclidinium in patients with COPD: a randomised, placebo-controlled studyEur Respir J201443728123949963
   PubMed Web of Science ®Google Scholar
• CopeSDonohueJFJansenJPComparative efficacy of long-acting bronchodilators for COPD – a network meta-analysisRespir Res201314
   Web of Science ®Google Scholar
• KarabisALindnerLMocarskiMHuismanEGreeningAComparative efficacy of aclidinium versus glycopyrronium and tiotropium, as maintenance treatment of moderate to severe COPD patients: a systematic review and network meta-analysisInt J COPD20138405423
   Google Scholar
• GSK Study 201280 [database on the internet] Available from: http://www.gsk-clinicalstudyregister.com/study/201280#psAccessed March 31, 2015
   Google Scholar
• PRISMA Guidelines [database on the internet] Available from: http://www.prisma-statement.org/Accessed April 1, 2015
   Google Scholar
• Allgemeine Methoden [database on the internet] Available from: https://www.iqwig.de/download/IQWiG_Methoden_Version_4-2.pdfAccessed June 25, 2015
   Google Scholar
• CopeSZhangJSaletanSSmiechowskiBJansenJPSchmidPA process for assessing the feasibility of a network meta-analysis: a case study of everolimus in combination with hormonal therapy versus chemotherapy for advanced breast cancerBMC Med2014129324898705
   PubMed Web of Science ®Google Scholar
• SalantiGIndirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis toolRes Synth Methods201238026062083
   PubMed Web of Science ®Google Scholar
• HoaglinDCHawkinsNJansenJPConducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: Part 2Value Health20111442943721669367
   PubMed Web of Science ®Google Scholar
• DiasSWeltonNJSuttonAJAdesAENICEDSU Technical Support Document 2: a generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trials [database on the internet] Available from: http://www.nicedsu.org.uk/TSD2%20General%20meta%20analysis%20corrected%2015April2014.pdfAccessed May 11, 2015
   Google Scholar
• DiasSWeltonNJCaldwellDMAdesAEChecking consistency in mixed treatment comparison meta-analysisStat Med20102993294420213715
   PubMed Web of Science ®Google Scholar
• SpiegelhalterDJBestNGCarlinBRvan der LindeABayesian measures of model complexity and fitJ R Stat Soc Series B Stat Methodol200264583616
   Web of Science ®Google Scholar
• LunnDJThomasABestNSpiegelhalterDWinBUGS – a Bayesian modelling framework: concepts, structure, and extensibilityStat Comput200010325337
   Web of Science ®Google Scholar
• VerkindreCBartFAguilaniuBThe effect of tiotropium on hyperinflation and exercise capacity in chronic obstructive pulmonary diseaseRespiration20067342042716484769
   PubMed Web of Science ®Google Scholar
• DonohueJFFogartyCLotvallJOnce-daily bronchodilators for chronic obstructive pulmonary disease indacaterol versus tiotropiumAm J Respir Crit Care Med201018215516220463178
   PubMed Web of Science ®Google Scholar
• NiewoehnerDERiceKCoteCPrevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trialAnn Intern Med200514331732616144890
   PubMed Web of Science ®Google Scholar
• CovelliHBhattacharyaSCassinoCConoscentiCKestenSAbsence of electrocardiographic findings and improved function with once-daily tiotropium in patients with chronic obstructive pulmonary diseasePharmacotherapy2005251708171816305289
   PubMed Web of Science ®Google Scholar
• CasaburiRMahlerDAJonesPWA long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary diseaseEur Respir J20021921722411866001
   PubMed Web of Science ®Google Scholar
• BrusascoVHodderRMiravitllesMKorduckiLTowseLKestenSHealth outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPDThorax20035839940412728159
   PubMed Web of Science ®Google Scholar
• GarciaRFA randomised, double-blind, placebo-controlled, 12 weeks trial to evaluate the effect of Tiotropium Inhalation Capsules on the magnitude of exercise, measured using an accelerometer, in patients with Chronic Obstructive Pulmonary Disease (COPD)Boehringer Ingelheim Trial Results NLM Identifier: NCT01443262007 Available from: http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/205/205.269.pdfAccessed October 19, 2015
   Google Scholar
• BatemanEDFergusonGTBarnesNDual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE studyEur Respir J2013421484149423722616
   PubMed Web of Science ®Google Scholar
• RennardSIScanlonPDFergusonGTACCORD COPD II: a randomized clinical trial to evaluate the 12-week efficacy and safety of twice-daily aclidinium bromide in chronic obstructive pulmonary disease patientsClin Drug Invest201333893904
   PubMed Web of Science ®Google Scholar
• GlaxoSmithKlineA multicenter trial comparing the efficacy and safety of GSK573719/GW642444 with GSK573719 and with tiotropium over 24 weeks in subjects with COPDClinical Study Report – DB2113374. NLM identifier: NCT13169132013 Available from: https://gsk.sylogent.com/files/sam-2588-gsk-113374-clinical-study-report-redact-v02.pdfAccessed October 19, 2015
   Google Scholar
• GlaxoSmithKlineA 24-week, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of GSK573719/GW642444 inhalation powder and the individual components delivered once-daily via a novel dry powder inhaler in subjects with chronic obstructive pulmonary diseaseClinical Study Report – DB2113373. NLM identifier: NCT13136502013 Available from: https://gsk.sylogent.com/files/sam-3623-gsk-113373-clinical-study-report-redact-v03.pdfAccessed October 19, 2015
   Google Scholar
• GlaxoSmithKline24-week trial comparing GSK573719/GW642444 with GW642444 and with tiotropium in chronic obstructive pulmonary diseaseClinical Study Report – DB2113360. NLM identifier: NCT13169002013 Available from: https://gsk.sylogent.com/files/sam-2504-gsk-113360-clinical-study-report-redact-v02.pdfAccessed October 19, 2015
   Google Scholar
• GlaxoSmithKlineA 12-week, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of GSK573719 delivered once-daily via a novel dry powder inhaler in subjects with chronic obstructive pulmonary diseaseClinical Study Report – AC4115408. NLM identifier: NCT13872302013 Available from: https://gsk.sylogent.com/files/sam-2802-gsk-115408-clinical-study-report-redact.pdfAccessed October 19, 2015
   Google Scholar
• TonnelABPerezTGrosboisJMVerkindreCBravoMLBrunMEffect of tiotropium on health-related quality of life as a primary efficacy endpoint in COPDInt J Chron Obstruct Pulmon Dis2008330131018686739
   PubMedGoogle Scholar
• JansenJPTrikalinosTCappelleriJCIndirect treatment comparison/network meta-analysis study questionnaire to assess relevance and credibility to inform health care decision making: an ISPOR-AMCP-NPC Good Practice Task Force ReportValue Health20141715717324636374
   PubMed Web of Science ®Google Scholar
• DonohueJFMinimal clinically important differences in COPD lung functionCOPD2005211112417136971
   PubMedGoogle Scholar
• JonesPWSt George’s respiratory questionnaire: MCIDCOPD20052757917136966
   PubMedGoogle Scholar
• MahlerDAWitekTJThe MCID of the transition dyspnea index is a total score of one unitCOPD200529910317136969
   PubMedGoogle Scholar
• ObaYLoneNAComparative efficacy of long-acting muscarinic antagonists in preventing COPD exacerbations: a network meta-analysis and meta-regressionTher Adv Respir Dis2015931525586493
   PubMed Web of Science ®Google Scholar
• GlaxoSmithKlineA randomized, parallel-group, open-label study to evaluate the efficacy and safety of umeclidinium (UMEC) 62.5 mcg compared with glycopyrronium 44 mcg in subjects with chronic obstructive pulmonary disease (COPD) Available from: http://www.gsk-clinicalstudyregister.com/study/201315#psAccessed June 25, 2015
   Google Scholar
• GlaxoSmithKlineA randomized, blinded, double-dummy, parallel-group study to evaluate the efficacy and safety of umeclidinium (UMEC) 62.5 mcg compared with tiotropium 18 mcg in subjects with chronic obstructive pulmonary disease (COPD) Available from: http://www.gsk-clinicalstudyregister.com/study/201316#psAccessed June 25, 2015
   Google Scholar
• BeierJKirstenAMMrozREfficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate-to-severe chronic obstructive pulmonary disease: results from a 6-week, randomized, controlled phase IIIb StudyCOPD20131051152223819698
   PubMedGoogle Scholar
• FuhrRMagnussenHSaremKEfficacy of aclidinium bromide 400 µg twice daily compared with placebo and tiotropium in patients with moderate to severe COPDChest201214174575221903737
   PubMed Web of Science ®Google Scholar
• ChapmanKRBeehKMBeierJA blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 studyBMC Pulm Med201414424438744
   PubMed Web of Science ®Google Scholar
• TashkinDCelliBKestenSLystigTDecramerMEffect of tiotropium in men and women with COPD: results of the 4-year UPLIFT (R) trialRespir Med20101041495150420418083
   PubMed Web of Science ®Google Scholar
• JonesPWRennardSIAgustiAEfficacy and safety of once-daily aclidinium in chronic obstructive pulmonary diseaseRespir Res2011125521518460
   PubMed Web of Science ®Google Scholar
• DonohueJFNiewoehnerDBrooksJO’DellDChurchASafety and tolerability of once-daily umeclidinium/vilanterol 125/25 mcg and umeclidinium 125 mcg in patients with chronic obstructive pulmonary disease: results from a 52-week, randomized, double-blind, placebo-controlled studyRespir Res2014157825015176
   PubMed Web of Science ®Google Scholar
• Spiriva Assessment of FEV1 (SAFE)The effect of inhaled tiotropium bromide (18 mcg once daily) on the change in FEV1 during long-term treatment in patients with COPD. A one-year parallel group, double-blind, randomised, placebo-controlled studyBoehringer Ingelheim Clinical Trial Register. NLM: NCT02772642005 Available from: http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clini-caltrial/com_EN/results/205/205.259_U05-3345.pdfAccessed October 19, 2015
   Google Scholar
• Spiriva® Assessment of FEV1 (SAFE)Boehringer Ingelheim2013 NLM identifier: NCT0277264. Available from: http://trials.boeh-ringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/205/205.259_U05-3345.pdfAccessed October 19, 2015
   Google Scholar
• Spiriva (Tiotropium Bromide) Assessment of FEV1 – (SAFE-Portugal)Boehringer Ingelheim2013 NLM identifier: NCT0239408. Available from: http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/205/205.282_U06-2124.pdfAccessed: October 19, 2015
   Google Scholar
• Evaluation of the long-term effects of Spiriva on lung function in COPD patientsBoehringer Ingelheim2005 NLM identifier: NCT0144339. Available from: https://clinicaltrials.gov/ct2/show/results/NCT0144339Accessed October 19, 2015
   Google Scholar
• CasaburiRBriggsDDDonohueJFSerbyCWMenjogeSSWitekTJThe spirometric efficacy of once-daily dosing with tiotropium in stable COPD – a 13-week multicenter trialChest20001181294130211083677
   PubMed Web of Science ®Google Scholar
• MoitaJBarbaraCCardosoJTiotropium improves FEV1 in patients with COPD irrespective of smoking statusPulm Pharmacol Ther20082114615117693107
   PubMed Web of Science ®Google Scholar
• VogelmeierCKardosPHarariSGansSJMStengleinSThirlwellJFormoterol mono- and combination therapy with tiotropium in patients with COPD: a 6-month studyRespir Med20081021511152018804362
   PubMed Web of Science ®Google Scholar
• KerwinEMD’UrzoADGelbAFLakkisHGarciaGECaractaCFEfficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I)COPD201299010122320148
   PubMedGoogle Scholar
• DonohueJFMaleki-YazdiMRKilbrideSMehtaRKalbergCChurchAEfficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPDRespir Med20131071538154623830094
   PubMed Web of Science ®Google Scholar
• WedzichaJADecramerMFickerJHAnalysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group studyLancet Respir Med2013119920924429126
   PubMed Web of Science ®Google Scholar
• JonesPWSinghDBatemanEDEfficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN studyEur Respir J20124083083622441743
   PubMed Web of Science ®Google Scholar